Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Myocet · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Mycet/Cyclophosphamid | ACTIVE_COMPARATOR | 4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile. |
| Myocet/Cyclophosphamide/Paclitaxel | ACTIVE_COMPARATOR | 2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile. |
| Name | Type | Description |
|---|---|---|
| Myocet | DRUG | - |
| Cyclophosphamide | DRUG | - |
| Paclitaxel | DRUG | - |
General Inclusion Criteria for ADAPT: * Female patients, age at diagnosis 18 years and above (consider patients at 70 years and above for ADAPT Elderly) * Candidate for chemotherapy on the basis of conventional criteria * Histologically confirmed unilateral primary invasive carcinoma of the breast ...
Myocet is an investigational small molecule being studied for the treatment of early primary breast cancer. It is currently in Phase 3 clinical development. The drug is being evaluated in a neoadjuvant setting, meaning it is given before primary treatment, in a completed clinical trial.
Myocet is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical research on the drug for the oncology therapeutic area, specifically targeting early primary breast cancer.
Myocet is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied for early primary breast cancer. The Phase 3 trial has been completed, with results expected to inform further development.
Myocet is associated with one completed Phase 3 clinical trial, identified as NCT02214381. This was a prospective, multicenter, open-label 12-week neoadjuvant trial in elderly patients with low response, enrolling 80 female patients aged 70 years and older in Germany.
Myocet is a distinct drug candidate developed by Teva Pharmaceutical Industries Limited. No alternative names for Myocet have been established in the available clinical trial information. It is being studied specifically for early primary breast cancer.